Introduction
============

Macular hole is a defect in the macular retina involving its full thickness from the internal limiting membrane (ILM) to the outer segment of the photoreceptor layer. It was first described in the ophthalmic literature in 1869 by Herman Knapp in a patient who suffered blunt injury in the eye.[@b1-opth-7-745] Macular holes are identified and staged with slit-lamp biomicroscopy. The introduction of optical coherence tomography (OCT) has further enhanced the assessment of the topographical details of macular holes.[@b2-opth-7-745],[@b3-opth-7-745] For over a century it was not believed to be treatable until 1991 when Kelly and Wendel reported a series of patients with macular holes treated with vitrectomy, gas tamponade, and facedown position.[@b4-opth-7-745] Previous studies have shown a relationship of the Macular Hole Index[@b5-opth-7-745] and the Hole Form Factor[@b6-opth-7-745] to a successful outcome. Our study was aimed to look at a possible relation of the macular hole depth to a favorable anatomical and visual outcome as well as the effect of autologous platelet injection in the surgical repair of macular holes.

Subjects and methods
====================

This is a retrospective study. It included 21 eyes of 21 consecutive patients with idiopathic full-thickness macular holes between November 2004 and February 2006. Patients with other coexisting macular pathologies such as macular degeneration or diabetic maculopathy were not included in the study. All patients were operated on by a single surgeon (MH). Informed consent was not obtained from the patients as OCT scans are routinely performed for patients with macular holes pre- and postoperatively. The study has been performed in accordance with the ethical standards of the Declaration of Helsinki.

Detailed history including duration of symptoms was obtained from each patient. After checking the best-corrected visual acuity (BCVA) with the Snellen chart (visual acuities were later converted to logMAR) and the intraocular pressure (IOP), the pupils were dilated. BCVA was measured with subjective and objective refraction by an experienced optometrist at the time that a patient was listed for surgery and at 6 months postoperatively. All patients then underwent slit-lamp examination to determine the status of the lens (phakic, aphakic, or pseudophakic) and assessment of the macula (noncontact biomicroscopy with 90D and contact biomicroscopy with Goldmann 3 mirror lens \[Haag-Streit, Bern, Switzerland\]).

OCT was then performed through a dilated pupil. The imaging involved multiple horizontal and vertical 5 mm scans with the fixation maintained. The OCT machine used was the Stratus OCT III version 5 (Carl Zeiss Meditec, Jena, Germany).

The macular hole diameters measured using the OCT were at the level of retinal pigment epithelium (maximum diameter), at the minimum extent of the hole (minimum diameter), and finally at the surface of the hole (rim diameter). The depth of the hole was also measured ([Figure 1](#f1-opth-7-745){ref-type="fig"}). There were one stage II, 17 stage III, and three stage IV macular holes.

All the patients underwent 23G three-port pars plana vitrectomy, autologous platelets injection followed by injection of gas tamponade (20% C~3~F~8~). All phakic patients (15 out of 21) also had phacoemulsification with posterior chamber implant combined with the above procedure. One hour after the surgery, the patients were asked to maintain a facedown posture (FDP) for 2 weeks, starting from the first postoperative day. The patients were instructed to maintain a FDP 45 minutes every hour.

The autologous platelet concentrate (APC) was prepared as described by previous authors.[@b7-opth-7-745],[@b8-opth-7-745] Fifty microliters of venous blood were drawn 1 hour before the operation. This blood sample was mixed with 6 mL of acid citrate dextrose and centrifuged at 280 g (1500 rpm) for 15 minutes. The platelet-rich plasma was then extracted and mixed with 1/8 volume of acid citrate dextrose and centrifuged again at 1000 *g* for 10 minutes. Finally, the platelet concentrate was mixed with 0.6 mL of sodium chloride. Two drops of 0.1 mL each were then injected in the eye. ILM peel was not attempted in any patient, as this technique was not favored by the operating surgeon.

Visual acuity, IOP and slit-lamp biomicroscopy were carried out on the first postoperative day, 1 week, 12 weeks, and 6 months after surgery. OCT was repeated at 1 month and 6 months. Postoperative anatomical success was defined as closure of the hole with no subretinal fluid at 6 months postoperatively. Pre- and postoperative BCVA were measured and compared in relation to the preoperative macular hole parameters.

Pearson's correlation coefficient was used to search for an existing relationship between BCVA at 6 months, BCVA improvement and macular hole parameters. *P* \< 0.05 showed statistical significance. All statistics were performed using MedCalc software (version 10.2; MedCalc, Ostend, Belgium).

Results
-------

A total of 21 eyes of 21 patients (male, 6; female, 15) were included in the study. Their age ranged from 56 to 77 years with a mean of 66.6 years. The majority of patients were phakic (15 out of 21) and six had uncomplicated cataract surgery with posterior chamber intraocular lens implant. The OCT parameters measured were: rim diameter (range: 299--1,372 μ; mean: 697 μ), maximum diameter (range: 336--1,384 μ; mean: 755 μ), minimum diameter (range: 207--798 μ; mean: 402 μ), and thickness (range: 113--805 μ; mean: 407 μ) ([Table 1](#t1-opth-7-745){ref-type="table"}).

Preoperative BCVA ranged from 1.3 to 0.5 logMAR with the majority of patients (20 out of 21) having an acuity from 1.3--0.8 logMAR. All the patients were followed up for 8 to 10 months after the operation. However, for the purpose of the study final outcomes (BCVA, confirmation of macular hole closure, reopening of the macular hole) were assessed at 6 months postoperatively. At that time their BCVA ranged from 0.0 to 0.8 log MAR with the majority of patients (18 out of 21) having a BCVA between 0.5 and 0.6 logMAR. Twenty out of 21 patients had improvement in visual acuity by two or more Snellen lines postoperatively. The eye that did not show significant visual improvement at the 6-month postoperative visit was previously one of the stage IV macular holes. Anatomical closure was confirmed with OCT in all the cases. We did not identify any reopenings of the macular holes.

We performed statistical analysis between macular hole parameters and BCVA at 6 months. There was no correlation between minimum diameter (Pearson's correlation coefficient, r = 0.0067; *P* = 0.97), maximum diameter (Pearson's correlation coefficient, r = 0.16; *P* = 0.48), height of the hole (Pearson's correlation coefficient, r = 0.25, *P* = 0.26), and BCVA at 6 months postoperatively.

We also investigated a possible correlation between macular hole parameters and BCVA improvement at 6 months. There was no correlation between minimum diameter (Pearson's correlation coefficient, r = −0.28; *P* = 0.22), maximum diameter (Pearson's correlation coefficient, r = −0.15; *P* = 0.5), height of the hole (Pearson's correlation coefficient, r = −0.24; *P* = 0.29), and BCVA improvement at 6 months postoperatively.

None of the patients had sight-threatening complications during the follow-up period. Four out of the 21 patients had increased IOP on the first postoperative day, which was treated with topical antiglaucoma medication.

Discussion
==========

OCT has helped the clinicians to understand better the subtle relationship between the vitreous and the retina and to measure the dimensions of the macular hole accurately, which is possible due to its high resolution. In addition, OCT can accurately confirm the anatomical closure of the macular hole postoperatively.[@b9-opth-7-745],[@b10-opth-7-745] Macular holes have been classified after surgery as elevated/open, flat/open, and flat/closed.[@b11-opth-7-745] In our series of patients, all macular holes were confirmed to be flat/closed.

Surgical intervention is the best management of macular holes as it offers better anatomical and functional results compared to their natural history.[@b4-opth-7-745],[@b12-opth-7-745] Since Kelly and Wendel's pioneer treatment of macular holes,[@b4-opth-7-745] a combination of different treatment options has been described. ILM peeling plays a pivotal role in the successful management of macular hole surgery (MHS).[@b5-opth-7-745],[@b10-opth-7-745],[@b13-opth-7-745]--[@b18-opth-7-745] Although the use of indocyanine green during ILM peeling has been associated with both retinotoxicity and damage of the retinal tissues,[@b16-opth-7-745],[@b19-opth-7-745]--[@b21-opth-7-745] it has been shown to achieve better anatomical and visual outcomes when compared with the nonpeeling technique[@b10-opth-7-745],[@b13-opth-7-745],[@b14-opth-7-745] especially in large and chronic holes.[@b17-opth-7-745]--[@b19-opth-7-745] Interestingly, Margherio et al[@b22-opth-7-745] did not show any difference between ILM peeling and the nonpeeling approach in stage II and III macular holes.

In order to avoid the complications of ILM peeling, the use of various adjuvants in MHS has been advocated by many authors. Such adjuvants include transforming growth factor β2,[@b7-opth-7-745],[@b23-opth-7-745] serum,[@b12-opth-7-745],[@b24-opth-7-745],[@b25-opth-7-745] thrombin,[@b26-opth-7-745] and autologous whole blood.[@b27-opth-7-745]

The most effective adjuvant however seems to be the APC.[@b8-opth-7-745],[@b27-opth-7-745]--[@b31-opth-7-745] In a randomized, control trial Paques et al[@b8-opth-7-745] included stage III and IV macular holes in their cohorts and reported a 98% vs 82% anatomical success in the platelet and nonadjuvant groups, respectively. However, there was no statistically significant difference in the visual outcome between the two groups despite the higher rate of anatomical closure in the platelet group. Similarly Hoerauf et al[@b27-opth-7-745] report that 93.9% of the macular holes treated with APC showed anatomic success compared to 36.4% success in the group treated with autologous whole blood. They included stage II, III, and IV macular holes in their study and showed that 15 out of 17 stage III macular holes and 6 out of 6 stage IV macular holes achieved anatomic success. Gaudric et al[@b28-opth-7-745] also showed better results when platelets were used as adjuvants in MHS (19 of 20 patients in the platelet group had anatomical closure vs 13 of 20 in the nonadjuvant group, all with stage II, III, and IV macular holes) although they recognize that their study is not a randomized controlled trial. Postoperative protocol in all three studies included FDP for 6--12 days. ILM peeling was not performed in any of these studies.

Postoperative FDP for MHS has been an issue of controversy over the years. The initial surgical technique by Kelly and Wendel[@b4-opth-7-745] involved SF~6~ injection and FDP for at least 1 week. Since then FDP was an integral part of a successful MHS, although it can be very demanding for patients of that age group (61 -- 77 years) and has been associated with medical complications.[@b30-opth-7-745] It was thought that the flotation forces of the bubble keeps the edges of the hole in contact with the retinal pigment epithelium and the FDP optimizes the effect of the bubble on the macular hole. The need for FDP was questioned by Tornambe et al[@b32-opth-7-745] who reported 79% anatomical success rate and 55% functional success rate without FDP. They supported the waterproofing theory according to which the gas bubble keeps the macula dry from the vitreous humor. Berger and Brucker[@b33-opth-7-745] showed that keeping the macula dry is more important than the buoyant forces of the bubble on the macula. These forces are actually far higher than the pressure gradient required to keep the retina attached to the choroid. Since then many authors favor the nonposturing approach to MHS.[@b34-opth-7-745]--[@b39-opth-7-745] In a recent study, Kapoor et al report 100% anatomical closure of longstanding macular holes in patients who could not maintain FDP with the use of autologous platelets.[@b40-opth-7-745] A systematic review about the need for postoperative FDP in MHS concluded that FDP is more useful for the success of MHS in larger idiopathic macular holes.[@b41-opth-7-745]

The surgical approach to our series of patients involved standard vitrectomy without ILM peeling. The procedure was augmented with injection of autologous platelets. Internal tamponade was achieved with intravitreal gas injection (C~3~F~8~). After surgery, all our patients were advised to rest in FDP 1 hour daily for 2 weeks. Patients were asked at every follow up regarding compliance and problems with FDP. None of them reported any medical complications and all of them confirmed that they were compliant with the instructions about posturing. Anatomical closure was confirmed in all cases and the majority of patients experienced improvement in visual acuity of more than two Snellen lines postoperatively. The final visual outcome was achieved 6 months postoperatively. The anatomical success rate of our series of patients is comparable to that of other authors[@b8-opth-7-745],[@b27-opth-7-745],[@b28-opth-7-745] who included in their studies stage II, III, and IV macular holes. We also report a high percentage of patients with ≥2 lines improvement of their BCVA. However, the final BCVA seems to be lower compared to that of previous publications.[@b7-opth-7-745],[@b27-opth-7-745]--[@b29-opth-7-745],[@b31-opth-7-745] We believe that this may be due to the very poor preoperative BCVA of our series as only one patient had a preoperative BCVA better than 0.8 logMAR. Many of our patients had large and longstanding macular holes, which accounts for the poor preoperative BCVA reported.

Historically, smaller macular holes have been associated with better anatomical and functional results. Previous publications have proposed two prognostic factors for the postoperative visual outcome.[@b5-opth-7-745],[@b6-opth-7-745] Tadayoni et al[@b13-opth-7-745] found that macular holes ≤ 400 μm have 100% anatomical success rate with vitrectomy and gas temponade followed by FDP for 10 days. On the other hand, holes ≥ 400 μm had a better postoperative anatomical outcome if the surgical technique was accompanied by ILM peeling. The level at which they measured the macular holes corresponds to the minimum diameter of the macular hole in our study. Similarly a recent study by Salter et al reported that macular holes with mid-hole diameter of \<500 μm had 0% failure rate, while those with a diameter above 1,000 μm had a 19.1% reopening rate.[@b42-opth-7-745]

We included 10 patients in our series with macular holes ≥ 400 μm who also had anatomical apposition postoperatively confirmed by OCT. Only one of them had greater than two Snellen lines improvement of their BCVA. We did not find any correlation between macular hole dimensions in BCVA and BCVA improvement. This is in contrast to a study by Ulrich et al[@b6-opth-7-745] who reported that BCVA was negatively correlated with minimum and base diameter (maximum diameter in our study). This can be attributed to the small size of our cohort, which makes statistical analysis and conclusions drawn from it less accurate. Furthermore the lack of correlation between macular hole parameters and BCVA improvement is in agreement with the findings of the above-mentioned study.[@b6-opth-7-745]

Our study carries several limitations. It is a retrospective case notes study, which includes a small cohort of patients compared to other studies in the literature. No control group was used and only three large stage IV macular holes were included. It reflects our experience with MHS in our center. However we feel that autologous platelets and 2 weeks of FDP may be considered as a safe adjunctive technique in MHS more so in the case of large holes and when ILM peeling is not performed.

To summarize, we did not find any role of macular hole parameters and indices in the final anatomical or visual outcome in our series as we achieved anatomical closure of all macular holes. Pars plana vitrectomy coupled with autologous injection of platelets and intraocular gas tamponade with postoperative FDP seems to play a major role in the final anatomical and visual outcome in MHS.
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###### 

Patients' characteristics and macular hole parameters[a](#tfn1-opth-7-745){ref-type="table-fn"}

  Patient   Sex    Age   Lens status    Rim diameter   Minimum diameter   Maximum diameter   Thickness   Preop VA   Postop VA
  --------- ------ ----- -------------- -------------- ------------------ ------------------ ----------- ---------- -----------
  1         F      61    Phakic         898            509                935                457         0.8        0.2
  2         F      66    Phakic         361            224                442                332         1.0        0.5
  3         F      75    Pseudophakic   648            436                755                449         1.0        0.5
  4         F      65    Pseudophakic   489            255                551                353         0.8        0.5
  5         M      56    Phakic         821            486                887                420         0.8        0.6
  6         F      64    Phakic         961            530                1002               501         1.0        0.5
  7         M      70    Pseudophakic   548            299                645                373         1.0        0.5
  8         F      63    Phakic         599            330                662                376         1.0        0.6
  9         F      75    Pseudophakic   634            436                715                380         1.0        0.0
  10        M      70    Phakic         821            523                908                464         0.8        0.5
  11        M      75    Pseudophakic   887            467                898                396         0.8        0.5
  12        F      67    Phakic         658            386                748                396         0.8        0.5
  13        F      73    Phakic         661            336                785                401         1.0        1.0
  14        F      71    Phakic         727            468                840                419         1.0        0.5
  15        F      68    Phakic         630            351                645                382         0.8        0.5
  16        F      72    Phakic         511            244                531                358         0.8        0.5
  17        F      70    Phakic         461            237                486                320         1.0        0.5
  18        F      77    Phakic         299            207                336                113         0.5        0.0
  19        F      66    Phakic         536            282                565                359         1.3        0.8
  20        M      68    Phakic         1122           640                1133               505         1.0        0.6
  21        F      67    Pseudophakic   1372           798                1384               805         1.3        0.5
            Mean                        697            402                755                407                    
            SD                          245            144                241                166                    

**Note:**

Macular hole diameters are given in μm.

**Abbreviations:** Preop VA, preoperative visual acuity (logMAR); Postop VA, postoperative visual acuity (logMAR); SD, standard deviation.
